Testing Nicotinamide for Improving Eye Function in Glaucoma Patients
Official title: Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients : Clinical Trial, Cross-over Design, Double-blind, Placebo-control, Randomized, Single-center Study
Run by CHA University · NCT06078605 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if Nicotinamide, a type of Vitamin B3, can help improve eye function in people with glaucoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | CHA University Academic / other |
| Locations | 1 site (Seongnam, Bundang-gu) |
| Trial ID | NCT06078605 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 19 years old diagnosed with early to moderate glaucoma and stable intraocular pressure.
✕Probably not a fit
Patients with congenital or secondary glaucoma, significant visual acuity loss, or a history of ocular inflammation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the efficacy of Nicotinamide, a form of Vitamin B3, on the functions of retinal ganglion cells in patients diagnosed with glaucoma. It employs a randomized, double-blind, placebo-controlled, cross-over design to ensure robust results. Participants will receive either Nicotinamide or a placebo, with the aim of assessing improvements in inner retinal function. The study is conducted at a single center, CHA University Bundang Medical Center.
Why it matters
Potential benefit: If successful, this treatment could enhance retinal function and potentially slow the progression of glaucoma in affected patients.
How similar studies have gone: While the use of Nicotinamide in this context is relatively novel, previous studies have indicated potential benefits of Vitamin B3 in retinal health.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult(Male or Female) over 19 years who were diagnosed with glaucoma. 2. In the case of participants receiving glaucoma treatment drugs, the investigator judges that the intraocular pressure remains constant for at least 1 year. 3. Intraocular pressure (IOP) \>/= 8mmHg and \< 18mmHg in each eye using Goldmann applanation tonometry prior to the screening visit 4. Adult participants diagnosed and treated for early-moderate glaucoma (VF mean deviation(MD) ≥-12 dB) 5. Have performed a reliable visual field in the last year, with \<33% fixation losses, false positives and false negatives. 6. Written consent voluntarily to participate in this clinical trial. Exclusion Criteria: 1. Patients with congenital glaucoma and secondary glaucoma caused by steroid drugs, etc. 2. BCVA (best-corrected visual acuity) Snellen equivalent of Snellen 20/80(logMar 0.25) or less. 3. Patients who have medical history of ocular inflammation 4. Patients with any ocular/systemic conditions that may affect electroretinogram parameter, or with visual field defects(Ischemic optic neuropathy, Proliferative diabetic retinopathy, Macular degeneration etc.) 5. Patients who have plans to intraocular surgery within the clinical trial period. 6. Patients with a history of significant ocular trauma within 6 months prior to the screening visit 7. Pregnant or lactating women. 8. A person who disagrees to contraception during a clinical trial period. 9. Patients with a history of malignancy within 5 years prior to the screening visit. 10. Patients that other researchers are determined inadequately.
Where it's running
-
CHA University Bundang Medical Center
Seongnam, Bundang-gu, Korea, Republic of Recruiting
Study contacts
- Principal investigator: Seungsoo Rho, MD, PhD — CHA Bundang Medical Center
- Study coordinator: Seungsoo Rho, MD, PhD
- Email: harryrho@gmail.com
- Phone: 82-10-9260-3173
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Balance training for people with glaucoma
A randomized study tests whether a structured eight-week balance program helps adults with glaucoma improve balance, reduce fall risk, and lessen fear of falling.
-
Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma
In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.
-
Comparison of FT-1000 non-contact tonometry with Goldmann applanation tonometry in glaucoma patients
This study tests whether the FT-1000 non-contact tonometer gives measurements that agree with the Goldmann applanation tonometer in adults with glaucoma.
-
Removing the ripcord from a glaucoma drainage device after 3 months
This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.
-
Glaucoma and Brain Changes: How Brain Structure and Size See What Glaucoma Is Doing
This study tests whether glaucoma is linked to broader brain changes by comparing brain MRI and eye health over time in people with glaucoma and matched controls.
-
Long-Term Results After Ab-interno Trabeculotomy for Glaucoma
This study tests whether ab-interno trabeculotomy with the Trabectome can provide sustained intraocular pressure reduction in glaucoma patients who had the procedure between 2019 and 2021.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.